- US: +1-408-610-2300
- Toll Free: +1-866-831-4085
- Become a Client
The global viral vectors and plasmid DNA manufacturing market size is forecasted to reach USD 11.2 billion by 2030, registering a CAGR of 14.7% from 2022 to 2030. A viral vector is an apparatus used to deliver genetic material in cells. A virus has an exceptional mechanism to transport the DNA in the cells that they infect. Specific viral vectors including adenovirus, retrovirus, simplex herpes virus, lentivirus, and others can be deployed to deliver genetic material onto the genomic cell composition.
The growth of the market is driven by the increase in global incidences of cancer and the increasing accessibility of sophisticated healthcare amenities. Additionally, gene therapy treatments including therapeutic gene vaccines, suicide gene therapy, anti-angiogenesis, and oncolytic virotherapy have been developed to cure different types of tumors. Such developments are opportunistic for market growth during the upcoming years.
The Adeno-associated Virus (AAV) vector type dominated the global market with a revenue share of over 18.9% in 2021. This is attributable to the development of orthopedic and ocular gene therapy treatments displaying enhanced efficiency and efficacy. In recent times, the adoption of AAV is considerably increasing across multiple therapeutic areas, thereby creating growth opportunities for the market demand.
The downstream processing workflow held the largest market share in 2021. The surging market demand for viral vectors owing to their escalating emergence in therapeutics has steered the need to optimize downstream processing. The methods for small-scale virus development typically include measures that are challenging to scale up. Resultantly, various commercial scalable processes are examined and optimized for ensuring the virus quantity along with the quality. These factors are boosting segmental growth.
The vaccinology application accrued the largest revenue share in the global market in 2021. The recent outbreak of COVID-19 impelled the deployment of viral vectors in vaccine research & development. The non-replicating viral vectors are deployed in the viral vector vaccines for COVID-19. The scientific community repurposed the existing methodologies catering to the need for developing an appropriate vaccine. Such advancements encourage product demand.
The Asia Pacific region is anticipated to expand at the fastest growth rate owing to the uptrend in patient influx, paired with the increase in research & development activities in viral vectors. Furthermore, individuals from western nations travel to various countries in Asia for stem cell therapy due to the less restrictive legal framework in the region. Moreover, Asia Pacific offers comparatively low-priced manufacturing and operating units for research activities. These factors play a significant role in supplementing the product demand in the market.
The global market is majorly fragmented with the existence of numerous well-established and small & medium-sized emerging market players. Several players opt for various growth strategies including mergers, acquisitions, and geographical expansion in economically favorable and emerging economies. For Instance, Cobra Biologics widened its facilities of manufacturing in the U.S and Europe in January 2021. It comprises the 4X expansion in the HQ DNA facility and the commencement of new manufacturing facilities in the European region. This aided in enhancing the company’s market position.
Research Support Specialist, USA